NERV · Minerva Neurosciences, Inc.
$4.02
-0.43 (-9.66%)
At close · Jul 24
Market Cap
$188.22M
Shares
46.59M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2024
Net Income
-$293.42M
-20492.7%
FY2025
Operating Margin
4.49%
FY2020
Diluted EPS
-$34.67
-18347.4%
FY2025
Operating Cash Flow
-$13.51M
+30.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $0 | $0 | $0 | $0 | $41.18M | $0 | $0 | $0 | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$2.05M | |
| $9.65M | $5.76M | $11.9M | $12.71M | $14.65M | $32.04M | $22.04M | $58.12M | $34.89M | $30.26M | $20.44M | $18.53M | $42.91M | |
| $18.22M | $9.34M | $9.95M | $10.41M | $10.58M | $13.33M | $17.29M | $17.74M | $16.84M | $10.91M | $9.75M | $7.58M | $11.96M | |
| — | $5442 | $5442 | $5442 | — | $16.01K | $16.01K | $17.47K | $17.47K | $11.09K | $16.53K | $17.28K | $33.87K | |
| $27.87M | $15.1M | $21.85M | $23.12M | $25.23M | $45.37M | $39.33M | $75.87M | $51.73M | $41.17M | $30.19M | $26.11M | $54.87M | |
| -$27.87M | -$15.1M | -$21.85M | -$23.12M | -$25.23M | -$45.37M | $1.85M | -$75.87M | -$51.73M | -$41.17M | -$30.19M | -$26.11M | -$54.87M | |
| — | — | — | — | — | — | 4.49% | — | — | — | — | — | — | |
| — | -$15.1M | -$21.84M | -$23.11M | — | -$45.35M | $1.86M | -$75.85M | -$51.71M | -$41.16M | -$30.17M | -$26.09M | -$54.84M | |
| $1.42M | $948.12K | $1.27M | $1.44M | $556.95K | $16.52K | $161.21K | $1.46M | $1.67M | $941.83K | $198.45K | $96.91K | — | |
| — | — | — | — | -$32.11M | -$51.71M | $1.94M | -$74.44M | -$50.17M | -$40.9M | — | — | — | |
| — | — | — | — | -$1.8M | -$1.8M | -$2.25M | -$2.25M | $0 | -$9.38M | — | — | — | |
| -$415.07M | -$293.42M | $1.44M | -$30.01M | -$32.11M | -$49.91M | $1.94M | -$72.18M | -$50.17M | -$31.52M | -$31.05M | -$27.08M | -$7.44M | |
| — | — | — | — | — | — | 4.71% | — | — | — | — | — | — | |
| -$60.06M | — | — | — | — | — | — | — | — | — | — | — | -$56.9M | |
| USD/shares | — | -$34.67 | $0.19 | -$4.61 | -$6.01 | -$9.36 | $0.40 | — | — | — | — | — | — |
| USD/shares | — | -$34.67 | $0.19 | -$4.61 | -$6.01 | -$9.36 | $0.40 | — | — | — | — | — | — |
| shares | — | 8.46M | 7.57M | 6.51M | 5.34M | 5.34M | 5.1M | 4.88M | 4.85M | 4.74M | 3.94M | 2.93M | 1.59M |
| shares | — | 8.46M | 7.57M | 6.51M | 5.34M | 5.34M | 5.11M | 4.88M | 4.85M | 4.74M | 3.94M | 2.93M | 1.59M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2018: $778 in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×